TCL Archive Cancer clinical trials cooperative groups are in jeopardy, and changes are needed to enable the system to survive, chairmen of the groups wrote in a paper submitted to NCI. White paper makes 25 recommendations, including changing system incentives, review process, group integration with centers and SPOREs, and inclusion in CaBIG. This 8-page issue includes full text of the white paper. April 2, 2004
TCL Archive Turmoil in Texas: DePinho Recommended AVEO Stock on CNBC Six Days After FDA Said New Trial Was Needed May 10, 2013
TCL Archive In Brief: NCI Still Undecided Over Small Hospital Segment Of CHOP; Multihospital Proposals Review Nov. 14-15 November 2, 1979
TCL Archive The shadow of Iressa lingered over the FDA Oncologic Drugs Advisory Committee as the panel voted down Genasense (Genta Inc.) and RSR13 (Allos Therapeutics Inc.) at its May 3 meeting. If anyone thought the bar had been lowered for drug approvals, they were mistaken. May 7, 2004
